How to Buy Palvella Therapeutics Stock
Palvella Therapeutics Inc
Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Palvella Therapeutics stock last closed at $98.58, up 1.86% from the previous day, and has increased 511.16% in one year. It has overperformed other stocks in the Biotechnology industry by 5.56 percentage points. Palvella Therapeutics stock is currently +782.54% from its 52-week low of $11.17, and -7.62% from its 52-week high of $106.71.
There are currently 11.84M PVLA shares outstanding. The market cap of PVLA is $1.17B. In the last 24 hours, 188,000 PVLA shares were traded.
How to Buy Palvella Therapeutics Stock
Not sure how to invest in Palvella Therapeutics stock? Here's how.
- Figure out where to buy Palvella Therapeutics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you choose where to buy Palvella Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Select your payment method and add your info.
- Analyze Palvella Therapeutics stock: The Palvella Therapeutics ticker symbol is PVLA. Is Palvella Therapeutics stock a good investment? Should you buy shares of PVLA? How do PVLA's underlying business fundamentals look? Do top analysts think Palvella Therapeutics is a good buy? Why has PVLA's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if PVLA is a good stock to buy).
- Make your PVLA purchase: Decide if you will purchase PVLA shares at the current market price or use a limit order to purchase PVLA shares at a particular price.
- Get the latest scoop on your investment in PVLA: Create a watchlist to monitor your investment in Palvella Therapeutics shares.
Step 1: Figure out where to buy Palvella Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy PVLA shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal information so you can buy PVLA today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start your new trading account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've opened your account on the best stock trading app for beginners, your next step is to transfer the money for your investment:
Watch the tutorial below for more details transferring funds into your brokerage account.
Step 4: Analyze Palvella Therapeutics stock
Once you have selected the best place to buy Palvella Therapeutics stock, it's crucial to analyze their stock before you invest, so you truly understand the risk and opportunity.
Palvella Therapeutics Numbers
PVLA Overview
WallStreetZen was designed to help part-time investors perform better fundamental analysis in less time.
You can see all of the due diligence checks on PVLA's stock page.
How is PVLA stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge PVLA's fair value.
Using relative valuations ratios:
- PVLA could be overvalued based on its P/B ratio of 30.16x, relative to Biotechnology industry P/B ratio of 5.32x
You can access additional valuation analysis on PVLA's stock here.
PVLA Financials at a glance
Positive Financial Indicators:
- PVLA has cash burn of 22590000. It has sufficient cash and short-term investments to cover this for at least one year.
- PVLA profit margin has gone up from -57.4% to 66,162.3% in the past year.
- There are more short-term assets than short-term liabilities on the PVLA balance sheet.
- Total PVLA debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the PVLA balance sheet.
- PVLA has $63.57M in cash and short term investments. This is sufficient to cover its annual cash burn of $22.59M.
Negative Financial Indicators:
- PVLA has a relatively high debt to equity ratio of 0.73.
Do analysts think it's a good time to buy PVLA stock
Out of 13 Wall Street analysts who research PVLA, the consensus analyst rating on Palvella Therapeutics is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
Latest PVLA Analyst Upgrades/Downgrades
Whitney Ijem, a top 4% analyst from Canaccord Genuity maintains PVLA with a strong buy rating and raises their PVLA price target from $90.00 to $148.00, on Nov 13, 2025.
Canaccord Genuity's Whitney Ijem raised their price target on Palvella Therapeutics (NASDAQ: PVLA) by 64.4% from $90 to $148 on 2025/11/14. The analyst maintained their Strong Buy rating on the stock.
Palvella Therapeutics reported its Q3 2025 earnings.
According to Whitney, the print was "ordinary," indicating everything is going as planned until top-line Ph2 CVM data is reported in mid-2025/12, and top-line Ph3 MLM data is released in Q1 2026.
Among the most noteworthy recent developments, according to the analyst, was the introduction of a new pharmaceutical candidate, QTORIN pitavastatin, for the treatment of DSAP (Disseminated Superficial Actinic Porokeratosis).
Earnings Report
For Q3 2025, Palvella Therapeutics reported:
- Loss per share of $1.03, compared to Q3 2024’s loss per share of $3.94.
Management did not provide EPS and revenue guidance in its press release.
Founder & CEO Wes Kaupinen commented: “As we enter year-end 2025, Palvella is now advancing innovative QTORIN™-derived therapies for four serious, rare skin diseases, each lacking a single FDA-approved therapy, allowing us to potentially be first for each of these deserving rare disease communities.
“Our lead product candidate, QTORIN™ rapamycin, continues to demonstrate its potential as a pipeline-in-a-product for mTOR-driven skin diseases, with a planned Phase 2 top-line readout in cutaneous venous malformations expected in mid-2025/12.
“This will be followed by a Phase 3 topline readout in microcystic lymphatic malformations which we anticipate in Q1 2026.
“Overall, we anticipate the next 18 months will be a catalyst-rich period highlighted by our objective to advance QTORIN™ rapamycin toward its first potential regulatory approval, with a steady flow of clinical, pre-commercialization, regulatory, and indication expansion milestones for QTORIN™ rapamycin and our additional QTORIN™ pipeline programs expected.
“Achievement of these milestones will advance our vision of becoming the leading biopharmaceutical company addressing serious, rare skin diseases with no FDA-approved therapies.”
Geulah Livshits, a top 2% analyst from Chardan Capital maintains PVLA with a strong buy rating and maintains their PVLA price target from $110.00 to $110.00, on Nov 13, 2025.
Danielle Brill, a top 14% analyst from Truist Securities maintains PVLA with a strong buy rating and raises their PVLA price target from $80.00 to $105.00, on Nov 10, 2025.
Ritu Baral, a top 22% analyst from TD Cowen maintains PVLA with a strong buy rating and raises their PVLA price target from $65.00 to $97.00, on Nov 6, 2025.
Joshua Schimmer, a top 1% analyst from Cantor Fitzgerald maintains PVLA with a strong buy rating and raises their PVLA price target from $120.00 to $200.00, on Nov 6, 2025.
You can dig deeper into what analysts are saying on the Palvella Therapeutics stock forecast page.
PVLA Momentum
Latest Insiders Trades at PVLA
In the past 12 months, executives and large shareholders at PVLA have bought more shares than they have sold.
Kathleen Goin, Chief Operating Officer of PVLA, was the latest PVLA insider to buy. They bought $15,379.56 worth of PVLA stock on Nov 19, 2025.
Dig into more about who owns PVLA stock here.
Does PVLA provide a stable income stream?
No, Palvella Therapeutics doesn't provide an income stream by paying out dividends.
PVLA Social Trading Data
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your PVLA purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly sufficient. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount, use a limit order.
Click the Open Trade button and your broker will place your order.
If you want more help with investing in stocks on eToro, watch the helpful video below:
Step 6: Get the latest scoop on your investment in PVLA
Now that you own some PVLA shares, you'll want to keep up with your shares.
Create a watchlist to keep track of your PVLA stock.
PVLA Feed
How to Buy Stock in Palvella Therapeutics
To reiterate, here are the 6 steps you need to take to buy Palvella Therapeutics stock right now:
- Figure out where to buy Palvella Therapeutics stock
- Open your brokerage account
- Deposit money your investment account
- Analyze Palvella Therapeutics stock
- Make your PVLA purchase
- Get the latest scoop on your investment in PVLA
If you are looking for a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to get updates on your new investment in Palvella Therapeutics, click the button below.
More Content You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.